###begin article-title 0
###xml 10 16 10 16 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA1 </italic>
###xml 20 26 20 26 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA2 </italic>
A role of BRCA1 and BRCA2 germline mutations in breast cancer susceptibility within Sardinian population
###end article-title 0
###begin p 1
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
###end p 1
###begin title 2
Background
###end title 2
###begin p 3
###xml 88 94 88 94 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA1 </italic>
###xml 98 104 98 104 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA2 </italic>
###xml 211 219 211 219 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA1-2 </italic>
###xml 378 386 378 386 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA1-2 </italic>
In recent years, numerous studies have assessed the prevalence of germline mutations in BRCA1 and BRCA2 genes in various cohorts. We here extensively investigated the prevalence and geographical distribution of BRCA1-2 mutations in the entire genetically-homogeneous Sardinian population. The occurrence of phenotypic characteristics which may be predictive for the presence of BRCA1-2 germline mutations was also evaluated.
###end p 3
###begin title 4
Methods
###end title 4
###begin p 5
###xml 186 194 186 194 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA1-2 </italic>
###xml 257 263 257 263 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA1 </italic>
###xml 267 273 267 273 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA2 </italic>
###xml 44 52 <span type="species:ncbi:9606">patients</span>
Three hundred and forty-eight breast cancer patients presenting a familial recurrence of invasive breast or ovarian carcinoma with at least two affected family members were screened for BRCA1-2 mutations by DHPLC analysis and DNA sequencing. Association of BRCA1 and BRCA2 mutational status with clinical and pathological parameters was evaluated by Pearson's Chi-Squared test.
###end p 5
###begin title 6
Results and Conclusion
###end title 6
###begin p 7
###xml 11 17 11 17 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA1 </italic>
###xml 23 29 23 29 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA2 </italic>
###xml 138 144 138 144 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA2 </italic>
###xml 183 191 183 191 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA1-2 </italic>
###xml 288 289 288 289 <italic xmlns:xlink="http://www.w3.org/1999/xlink">a</italic>
###xml 372 395 372 395 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA2 c.8764_8765delAG </italic>
###xml 442 443 442 443 <italic xmlns:xlink="http://www.w3.org/1999/xlink">b</italic>
###xml 510 516 510 516 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA2 </italic>
###xml 553 559 553 559 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA1 </italic>
###xml 575 576 575 576 <italic xmlns:xlink="http://www.w3.org/1999/xlink">c</italic>
###xml 657 663 657 663 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA1 </italic>
###xml 927 935 927 935 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA1-2 </italic>
Overall, 8 BRCA1 and 5 BRCA2 deleterious mutations were detected in 35/348 (10%) families; majority (23/35;66%) of mutations was found in BRCA2 gene. The geographical distribution of BRCA1-2 mutations was related to three specific large areas of Sardinia, reflecting its ancient history: a) the Northern area, linguistically different from the rest of the island (where a BRCA2 c.8764_8765delAG mutation with founder effect was predominant); b) the Middle area, land of the ancient Sardinian population (where BRCA2 mutations are still more common than BRCA1 mutations); and c) the South-Western area, with many Phoenician and Carthaginian locations (where BRCA1 mutations are prevalent). We also found that phenotypic features such as high tumor grading and lack of expression of estrogen/progesterone receptors together with age at diagnosis and presence of ovarian cancer in the family may be predictive for the presence of BRCA1-2 germline mutations.
###end p 7
###begin title 8
Background
###end title 8
###begin p 9
###xml 133 134 133 134 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B1">1</xref>
###xml 280 281 280 281 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B2">2</xref>
###xml 536 537 536 537 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B3">3</xref>
###xml 538 539 538 539 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B4">4</xref>
###xml 657 663 657 663 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA1 </italic>
###xml 680 686 680 686 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA2 </italic>
###xml 720 721 720 721 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B5">5</xref>
###xml 722 723 722 723 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B6">6</xref>
###xml 795 801 795 801 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA1 </italic>
###xml 813 819 813 819 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA2 </italic>
###xml 862 867 862 867 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA </italic>
###xml 951 952 951 952 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B7">7</xref>
###xml 47 52 <span type="species:ncbi:9606">women</span>
###xml 851 856 <span type="species:ncbi:9606">women</span>
Breast cancer is the most common malignancy in women in Western countries, currently accounting for one third of all female cancers [1]. In Sardinia, breast cancer represents the principal death-causing malignancy, with an incidence similar to that observed in western countries [2]. Familial aggregation is thought to account for 5-10% of all breast cancer cases, and germline mutations in different genes involved in pathways critical to maintain the genomic integrity have accounted for less than 25% of the inherited breast cancer [3,4]. Part of this familial clustering shows autosomal dominant inheritance with high penetrance due to mutations in the BRCA1 (MIM 113705) and BRCA2 (MIM 600185) breast cancer genes [5,6]. Cumulative breast cancer risks by age 70 are estimated to be 65% for BRCA1 and 45% for BRCA2 mutation carriers. In addition, women with BRCA mutations are at significant risk to develop ovarian cancer and other malignancies [7].
###end p 9
###begin p 10
###xml 159 160 159 160 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B8">8</xref>
###xml 161 162 161 162 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B9">9</xref>
###xml 217 223 217 223 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA1 </italic>
###xml 227 233 227 233 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA2 </italic>
###xml 743 745 743 745 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B10">10</xref>
###xml 746 748 746 748 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B13">13</xref>
###xml 780 788 780 788 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA1-2 </italic>
###xml 902 904 902 904 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B14">14</xref>
###xml 1040 1042 1040 1042 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B15">15</xref>
###xml 1043 1045 1043 1045 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B16">16</xref>
###xml 1275 1277 1275 1277 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B17">17</xref>
###xml 1346 1352 1346 1352 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA1 </italic>
###xml 1356 1362 1356 1362 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA2 </italic>
###xml 1548 1554 1548 1554 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA1 </italic>
###xml 1557 1563 1557 1563 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA2 </italic>
###xml 1725 1726 1725 1726 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B7">7</xref>
###xml 1575 1583 <span type="species:ncbi:9606">patients</span>
###xml 1671 1676 <span type="species:ncbi:9606">women</span>
Hundreds of mutations among breast/ovarian cancer families have been found in these two genes. According to the Breast Cancer Information Core (BIC) database [8,9], about two thirds of germline variants identified in BRCA1 and BRCA2 are unique; the remaining ones are recurrent founder mutations which have been described in different ethnic groups and populations. Therefore, the mutation spectrum and prevalence of mutation carriers with breast or ovarian cancer depends on the population studied, and displays considerable variation based on ethnic and geographical diversity. In Italy, 4-27% of the identified mutations recurred among apparently unrelated families, while a regional founder effect has been demonstrated for few mutations [10-13]. In Sardinia, contribution of BRCA1-2 mutations to breast cancer predisposition has been reported for populations from the Northern part of the island [14]. Sardinian population shows strong founder effects for several genetic diseases with some geographical differences within the island [15,16]; indeed, some genetic heterogeneity has been described within the coastal or proximal-to-coast regions, which have suffered repeated invasions over many years, in comparison to the most internal and isolated part of the island [17]. On this regard, the assessment of both spectrum and prevalence of BRCA1 and BRCA2 mutations across the entire island as well as their predictive significance in this population is needed. Nevertheless, assessment of the likelihood of carrying deleterious mutations in BRCA1 or BRCA2 genes among patients who present high-risk cancer evaluation clinics will provide more accurate guidance to women and families about considering genetic testing [7].
###end p 10
###begin p 11
###xml 66 74 66 74 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA1-2 </italic>
###xml 211 219 211 219 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA1-2 </italic>
###xml 273 281 <span type="species:ncbi:9606">patients</span>
Here we report on the prevalence and geographical distribution of BRCA1-2 mutations within the entire Sardinian population. We also investigated the existence of any significant association between mutations in BRCA1-2 genes and phenotypic characteristics of breast cancer patients that could drive specific treatment and influence the process of mutation testing.
###end p 11
###begin title 12
Methods
###end title 12
###begin title 13
Family selection
###end title 13
###begin p 14
###xml 850 852 850 852 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B18">18</xref>
###xml 853 855 853 855 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B19">19</xref>
###xml 42 50 <span type="species:ncbi:9606">patients</span>
###xml 163 171 <span type="species:ncbi:9606">patients</span>
###xml 896 904 <span type="species:ncbi:9606">patients</span>
A total of 1,085 unselected breast cancer patients was recruited from all clinics at the Universities and Hospitals across the Sardinia island. To avoid any bias, patients were consecutively collected from January 1998 to December 2003 and were enrolled regardless of age at diagnosis, family history status or disease features. Sardinian origin was ascertained in all cases through genealogical studies. Family history of cancer was evaluated through specific questionnaires during the follow-up visits at the participating institutions. Three-hundred-forty-eight (32%) presented a familial recurrence of invasive breast or ovarian carcinoma: 237 originated from North Sardinia, 66 from Middle and 45 from South. Part of the present cohort (112 familial cases with at least three affected members) had been already included in our previous studies [18,19]. The remaining 737 (68%) breast cancer patients were sporadic cases.
###end p 14
###begin p 15
###xml 6 14 <span type="species:ncbi:9606">patients</span>
###xml 167 174 <span type="species:ncbi:9606">patient</span>
Among patients with a family history of breast/ovarian cancer, 131/348 (37.6%) fulfilled the selection criterion for "high risk" families: presence of a breast cancer patient diagnosed before age 50 years and having at least one first- or second-degree relative diagnosed with breast cancer before 50 years of age or ovarian cancer at any age.
###end p 15
###begin p 16
###xml 261 262 261 262 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T1">1</xref>
###xml 365 372 <span type="species:ncbi:9606">patient</span>
Of those, 73 originated from North Sardinia, 21 from the Middle and 37 from the South. The 81% of "high risk" families presented with breast cancer and the 12% with both breast and ovarian cancer. Male breast cancer was present in the 7% of the families (Table 1). The remaining 217 families were categorized as "no high risk" families: presence of a breast cancer patient having at least one first- or second-degree relative who is diagnosed with breast cancer or ovarian cancer at any age.
###end p 16
###begin p 17
###xml 0 6 0 6 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA1 </italic>
###xml 10 16 10 16 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA2 </italic>
BRCA1 and BRCA2 mutational analysis
###end p 17
###begin p 18
###xml 0 9 0 9 <bold xmlns:xlink="http://www.w3.org/1999/xlink">High risk</bold>
###xml 224 236 224 236 <bold xmlns:xlink="http://www.w3.org/1999/xlink">No high risk</bold>
###xml 39 46 <span type="species:ncbi:9606">patient</span>
###xml 266 273 <span type="species:ncbi:9606">patient</span>
High risk: presence of a breast cancer patient diagnosed before age 50 years and having at least one first- or second-degree relative who is diagnosed with breast cancer before 50 years of age or ovarian cancer at any age). No high risk: presence of a breast cancer patient having at least one first- or second-degree relative who is diagnosed with breast cancer or ovarian cancer at any age. BC, breast cancer; OC, ovarian cancer; MBC, male breast cancer.
###end p 18
###begin p 19
* including 112 families already reported in our previous studies
###end p 19
###begin p 20
###xml 400 408 <span type="species:ncbi:9606">patients</span>
According to number of breast/ovarian cancer in the families, we had 75 families with 3 or more affected members and 47 families with two affected members among the "high risk" cases; 67 families had 3 or more affected members and 70 families had two affected members among the "no high risk" cases. Information on total number of affected family members were uncertain or not available for 9 and 80 patients in the "high risk" and "no high risk" groups, respectively.
###end p 20
###begin p 21
Clinical and pathological characteristics of the breast cancer probands including age at diagnosis, mono- or bilateral tumour location, stage of disease, tumour-node-metastasis system status, tumour grading, estrogen/progesterone receptor status, were confirmed by medical records and pathology reports.
###end p 21
###begin p 22
###xml 0 8 <span type="species:ncbi:9606">Patients</span>
Patients were informed about the aims of the study; blood samples for genetic testing were drawn after obtaining their written consent. The study was reviewed and approved by the ethical review boards of the participating Institutions accounting for samples' collection (University of Sassari; Azienda Sanitaria Locale of Sassari, Nuoro and Cagliari).
###end p 22
###begin title 23
Mutation detection
###end title 23
###begin p 24
###xml 72 78 72 78 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA1 </italic>
###xml 82 88 82 88 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA2 </italic>
###xml 268 270 268 270 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B20">20</xref>
###xml 340 346 340 346 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA1 </italic>
###xml 350 356 350 356 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA2 </italic>
###xml 728 730 728 730 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B18">18</xref>
###xml 731 733 731 733 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B19">19</xref>
###xml 1178 1180 1178 1180 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B21">21</xref>
###xml 1319 1321 1319 1321 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B22">22</xref>
###xml 1322 1324 1322 1324 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B24">24</xref>
###xml 1289 1294 <span type="species:ncbi:9606">Human</span>
Mutation analysis of coding sequences and intron-exon boundaries of the BRCA1 and BRCA2 genes was carried out in the series of 348 probands from families with hereditary breast cancer. Genomic DNA was obtained from isolated white blood cells by salting out procedure [20]. Mutation detection for all coding regions and splice boundaries of BRCA1 and BRCA2 genes was performed by single strand conformation polymorphism (SSCP) for a small fraction of cases (27 family probands); all remaining cases underwent mutational screening by denaturing high performance liquid chromatography (DHPLC), using the WAVE Nucleic Acid Fragment Analysis System (Transgenomic, Omaha, NE), followed by automated sequencing as previously reported [18,19]. To confirm that each germline variant detected by sequencing was a real mutation and not a polymorphism, 103 unrelated normal individuals (corresponding to 206 chromosomes), originating from the same geographical area and with no family history for breast cancer, were used as controls and screened for each gene variant identified. For sequence homology searches, National Center for Biotechnology Information Blast database  has been used [21]. All identified variants were verified for their existence and nomenclature into the BIC database  and the Human Gene Mutation Database [22-24].
###end p 24
###begin title 25
Statistical Analysis
###end title 25
###begin p 26
###xml 143 148 143 148 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA1</italic>
###xml 150 155 150 155 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA2</italic>
###xml 474 476 474 476 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B25">25</xref>
###xml 681 683 681 683 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B26">26</xref>
###xml 892 900 892 900 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA1-2 </italic>
The Pearson's Chi-Squared test was used for assessing the existence of any correlation between occurrence of deleterious germline mutations in BRCA1, BRCA2, or either gene and probands' characteristics. The following variables and categories were defined and included in our analyses: presence of ovarian or male breast cancer in family, synchronous or asynchronous bilateral breast carcinoma, age at diagnosis, histological tumor grade as standardized by Elston and Ellis [25], disease stage (pathological primary tumor size, pathological nodal status, presence of metastases) according to TNM classification which describes the anatomical extended of the disease by Sobin et al [26], estrogen and progesterone receptor status. The exact coefficient for sample proportion analysis was calculated to determine all of the significant parameters (below the 0.05 level). Odds ratios of carrying BRCA1-2 mutations were estimated by the logistic regression model and reported with 95% confidence interval (95% CI). All analyses were performed with the statistical package SPSS/7.5 for Windows.
###end p 26
###begin title 27
Results
###end title 27
###begin title 28
Family screening for BRCA1 and BRCA2 mutations
###end title 28
###begin p 29
###xml 103 109 103 109 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA1 </italic>
###xml 113 119 113 119 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA2 </italic>
###xml 300 301 300 301 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T1">1</xref>
###xml 499 507 499 507 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA1-2 </italic>
###xml 836 844 836 844 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA1/2 </italic>
###xml 1091 1099 1089 1097 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA1-2 </italic>
Genomic DNA from 348 probands of breast-ovarian cancer families was screened for germline mutations in BRCA1 and BRCA2 genes. Overall, deleterious germline mutations were detected in 35/348 (10%) familial cases: 23/131 (17.5%) among "high-risk" and 12/217 (5.5%) among "no high-risk" families (Table 1). Families with 3 or more BC cases, including the 112 reported in our previous studies, showed a prevalence rate of 11.7% (17/145). Presence of ovarian cancer in family increased the occurrence of BRCA1-2 germline mutations in either the subset of "high-risk" families (5/16; 31%) or the group of "no high-risk" families (1/8; 12.5%). No similar variation of mutation rates was observed in families presenting a male member with breast cancer. Stratification of families according to number of breast-ovarian cancer cases showed that BRCA1/2 positivity was significantly higher in families with 3 or more affected members than those with only two cases, with frequencies of 11.7% and 3.5%, respectively. Among 41/131 "high-risk" probands diagnosed at age </=40 years, 12 (29%) presented a BRCA1-2 germline mutation.
###end p 29
###begin p 30
###xml 131 136 131 136 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA </italic>
The overall mutation prevalence was 7% in North Sardinia and 17% and 18% in families from Middle and South Sardinia, respectively. BRCA positivity accounts for 11% (8/73), 38% (8/21) and 19% (7/37) in "high risk" families from these geographical areas (data not shown).
###end p 30
###begin title 31
Spectrum of BRCA1-2 mutations in Sardinia
###end title 31
###begin p 32
###xml 20 26 20 26 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA1 </italic>
###xml 41 47 41 47 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA2 </italic>
###xml 176 182 176 182 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA1 </italic>
###xml 193 198 193 198 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA2</italic>
###xml 210 216 210 216 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA1 </italic>
###xml 223 229 223 229 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA2 </italic>
###xml 347 352 347 352 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA2</italic>
###xml 378 383 378 383 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA1</italic>
###xml 616 617 616 617 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T2">2</xref>
###xml 689 710 689 710 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA1 c.916_917delTT </italic>
###xml 744 750 744 750 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA1 </italic>
###xml 825 842 825 842 <italic xmlns:xlink="http://www.w3.org/1999/xlink">c.8764_8765delAG </italic>
###xml 846 869 846 869 <italic xmlns:xlink="http://www.w3.org/1999/xlink">c.3950_3952delTAGinsAT </italic>
###xml 906 912 906 912 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA2 </italic>
###xml 918 926 <span type="species:ncbi:9606">patients</span>
Overall, 8 distinct BRCA1 and 5 distinct BRCA2 pathogenic mutations were found in 35 (10%) out of 348 breast-ovarian cancer families; 11 "high-risk" families were positive for BRCA1 and 12 for BRCA2, whereas 1 BRCA1 and 11 BRCA2 mutations were identified in "no high-risk" families. Therefore, majority (23/35; 66%) of such mutations was found in BRCA2, and 12/35 (34%) were in BRCA1. All mutations were absent in normal genomic DNA from 103 unrelated healthy individuals (corresponding to 206 control chromosomes) and were classified as disease-causing variants due to their predicted effects on proteins. In Table 2, all germline mutations detected in our series have been reported. The BRCA1 c.916_917delTT mutation was the most represented BRCA1 variant (three positive families out of 348 cases; 1%), while the variants c.8764_8765delAG and c.3950_3952delTAGinsAT were the most recurrent mutations in BRCA2 among patients with a positive family history [13/348 (4%) and 7/347 (2%), respectively]. These mutations showed similar frequencies in both the "high risk" and no "high risk" groups (6.8% vs 5%).
###end p 32
###begin p 33
###xml 0 6 0 6 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA1 </italic>
###xml 10 16 10 16 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA2 </italic>
###xml 38 39 38 39 <sup xmlns:xlink="http://www.w3.org/1999/xlink">a</sup>
BRCA1 and BRCA2 pathogenetic mutationsa
###end p 33
###begin p 34
###xml 0 2 0 2 <sup xmlns:xlink="http://www.w3.org/1999/xlink">a </sup>
###xml 79 81 79 81 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B22">22</xref>
###xml 126 131 126 131 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA1</italic>
###xml 142 147 142 147 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA2</italic>
a Consensus nomenclature of mutations according to den Dunnen and Antonarakis [22]. Mutations refer to the GenBank accession #BRCA1: no.  and BRCA2: no. ).
###end p 34
###begin p 35
###xml 22 23 22 23 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T2">2</xref>
###xml 25 26 25 26 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T4">4</xref>
###xml 36 42 36 42 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA1 </italic>
###xml 67 73 67 73 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA2 </italic>
###xml 186 188 186 188 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B23">23</xref>
###xml 189 191 189 191 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B24">24</xref>
###xml 234 242 234 242 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA1-2 </italic>
###xml 456 457 456 457 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T3">3</xref>
###xml 156 161 <span type="species:ncbi:9606">Human</span>
As indicated in Table 2, 4 out of 8 BRCA1 mutations and 2 out of 5 BRCA2 mutations have not been previously reported in either the BIC database.  or in the Human Gene Mutation Database [23,24]. Besides deleterious mutations, complete BRCA1-2 screening identified 32 missense mutations and 16 intronic variations: 21 already described polymorphisms, 14 variants of unknown clinical significance and 13 novel variants not reported in the BIC database (Table 3).
###end p 35
###begin p 36
###xml 26 32 26 32 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA1 </italic>
###xml 36 41 36 41 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA2</italic>
Other genetic variants in BRCA1 and BRCA2
###end p 36
###begin p 37
###xml 55 60 55 60 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA </italic>
Logistic regression analysis to identify predictors of BRCA mutations
###end p 37
###begin p 38
###xml 65 73 65 73 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA1-2 </italic>
###xml 102 103 102 103 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1</xref>
###xml 109 115 109 115 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA1 </italic>
###xml 239 280 239 280 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA1 c.3823_3826delACAA, BRCA1 c.300 T&gt;G</italic>
###xml 304 320 304 320 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA1 c.1632 A&gt;T</italic>
###xml 339 360 339 360 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA1 c.916_917delTT </italic>
###xml 438 494 438 494 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA2 c.8764_8765delAG and BRCA2 c.3950_3952delTAGinsAT </italic>
###xml 584 590 584 590 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA2 </italic>
The geographical origin of the families positive for deleterious BRCA1-2 mutations is shown in Figure 1. The BRCA1 variants occurred in families originating from different areas of the island: 7 probands from the South, 2 from the Middle (BRCA1 c.3823_3826delACAA, BRCA1 c.300 T>G) and 1 from the North (BRCA1 c.1632 A>T). Carriers of the BRCA1 c.916_917delTT mutation were identified in three unrelated families from the South area. The BRCA2 c.8764_8765delAG and BRCA2 c.3950_3952delTAGinsAT variants were found in probands from the North and Middle Sardinia, whereas the remaining BRCA2 variants were detected in single families from the Central-East coast and South.
###end p 38
###begin p 39
###xml 0 67 0 67 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Geographical distribution of BRCA1-2 mutations carriers in Sardinia</bold>
###xml 174 180 174 180 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA1 </italic>
###xml 183 189 183 189 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA2 </italic>
###xml 211 217 211 217 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA1 </italic>
###xml 241 247 241 247 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA1 </italic>
###xml 280 286 280 286 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA1 </italic>
###xml 318 323 318 323 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA1</italic>
###xml 348 354 348 354 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA1 </italic>
###xml 382 388 382 388 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA1 </italic>
###xml 413 419 413 419 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA1 </italic>
###xml 454 460 454 460 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA1 </italic>
###xml 486 492 486 492 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA2 </italic>
###xml 532 538 532 538 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA2 </italic>
###xml 564 586 564 586 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA2 c.6023_6024delTA</italic>
###xml 601 607 601 607 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA2 </italic>
###xml 637 643 637 643 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA2 </italic>
###xml 113 121 <span type="species:ncbi:9606">patients</span>
Geographical distribution of BRCA1-2 mutations carriers in Sardinia. Symbols indicate villages of origin for the patients presenting deleterious germline mutations in either BRCA1 or BRCA2 genes: "green square" BRCA1 c.300 T>G; green circle BRCA1 c.916_917delTT; "green triangle" BRCA1 c.1099_1100delCA; "green arrow" BRCA1c.1499insA; "green heart"BRCA1 c.1632 A>T; "green diamond" BRCA1 c.1638 A>T;"green clubs" BRCA1 c.3823_3826delACAA; "green spades" BRCA1 c.4575delA; "blue square" BRCA2 c.3950_3952delTAGinsAT; "blue triangle" BRCA2 c.6586 C>G; "blue circle" BRCA2 c.6023_6024delTA; "blue arrow" BRCA2 c.8764_8765delAG; "blue heart"BRCA2 c.8559+1G>T. Dashed lines delimit the three geographical regions reported in the text.
###end p 39
###begin title 40
Correlation between BRCA1-2 mutations and probands' phenotype characteristics
###end title 40
###begin p 41
###xml 18 19 18 19 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T4">4</xref>
###xml 70 78 70 78 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA1-2 </italic>
###xml 425 433 425 433 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA1-2 </italic>
###xml 569 577 569 577 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA1-2 </italic>
###xml 636 644 <span type="species:ncbi:9606">patients</span>
As shown in Table 4, univariate analysis indicated that presence of a BRCA1-2 mutation correlated significantly with earlier diagnosis age (P = 0.046), classification of the family as "high risk" (P = 0.002), recurrence in the family of ovarian cancer (P = 0.006), and development of a bilateral disease (P = 0.038). Considering the pathological parameters of primary tumors, no statistically significant correlation between BRCA1-2 mutations and primary tumor size (T) or axillary nodal status (N) or distant localization of the disease (M) was observed. However, the BRCA1-2 mutation rates were significantly higher in the subsets of patients with a more undifferentiated primary carcinoma (tumor grading 3-4, P < 0.001) and lack of expression of estrogen receptor (ER-, P = 0.002) or progesterone receptor (PR-, P = 0.007).
###end p 41
###begin title 42
Discussion
###end title 42
###begin p 43
###xml 50 58 50 58 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA1-2 </italic>
###xml 266 268 266 268 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B27">27</xref>
###xml 269 271 269 271 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B28">28</xref>
###xml 288 296 288 296 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA1-2 </italic>
###xml 80 88 <span type="species:ncbi:9606">patients</span>
###xml 444 452 <span type="species:ncbi:9606">patients</span>
In this study, we have reported the prevalence of BRCA1-2 germline mutations in patients with a positive family history of breast and/or ovarian cancer from Sardinia, whose population shows genetic peculiarity due to geographical isolation and strong genetic drift [27,28]. Prevalence of BRCA1-2 mutations may indeed vary among distinct populations due to concurrence of different environmental factors and genetic backgrounds; in other words, patients origin may strongly account for different mutation rates in candidate genes.
###end p 43
###begin p 44
###xml 63 69 63 69 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA1 </italic>
###xml 72 78 72 78 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA2 </italic>
###xml 144 150 144 150 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA1 </italic>
###xml 202 208 202 208 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA2 </italic>
###xml 260 265 260 265 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA </italic>
###xml 763 768 761 766 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA </italic>
In the present study, a germline pathogenic mutation in either BRCA1 or BRCA2 was identified in 10% of screened breast-ovarian cancer families (BRCA1 mutations were detected in about 3% of cases, while BRCA2 mutations were identified in about 7% of families). BRCA positivity reached 17.5% when considering the "high risk" families, 29% in families with probands diagnosed at age </=40 years and 31% in the presence of ovarian cancer in the family. Prevalence rate in "high risk" families was higher than that of families with 3 or more affected member regardless of age at onset (11.7%). These results confirm that clinical characteristics such as ovarian cancer in the family, age at diagnosis and number of cases are good predictors for the likelihood to be a BRCA mutation carrier.
###end p 44
###begin p 45
###xml 26 34 26 34 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA1-2 </italic>
###xml 251 255 251 255 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA</italic>
###xml 323 325 323 325 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B14">14</xref>
###xml 326 328 326 328 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B18">18</xref>
###xml 353 358 353 358 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA </italic>
###xml 550 552 550 552 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B10">10</xref>
###xml 553 555 553 555 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B13">13</xref>
###xml 556 558 556 558 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B29">29</xref>
###xml 559 561 559 561 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B32">32</xref>
###xml 1004 1009 1004 1009 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA </italic>
###xml 1402 1407 1402 1407 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA </italic>
###xml 1661 1663 1661 1663 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B33">33</xref>
###xml 64 72 <span type="species:ncbi:9606">patients</span>
The overall prevalence of BRCA1-2 mutations among breast cancer patients from the entire Sardinia was quite similar to that previously reported for breast-ovarian cancer families originating from the Northern part of the island (for both studies, 15% BRCA-positive carriers were observed in breast-ovarian cancer families [14,18]. However prevalence of BRCA deleterious mutations was higher in Middle Sardinia (38% vs 11% in the North. and 19% in the South). When compared to many other Italian and European studies, the frequency is relatively low [10-13,29-32]. Since the sensitivity of mutation detection methods is not complete, some mutations may have remained undetected in the present study. Large genomic deletions, which do escape detection by both DHPLC and direct sequencing may account for a fraction of mutation-negative breast and ovarian cancer families in Sardinia. Overall and even considering a lack of sensitivity of the screening approach used in the present study, the prevalence of BRCA mutations in Sardinian families remains low. The selection criterion of two close relatives with breast cancer before the age of 50 years, used in this study, may somehow explain this low prevalence rate, though it is not possible to exclude that a specific genetic background may play a role on breast cancer susceptibility among Sardinian population. Noteworthy, a similar low prevalence of BRCA mutations was reported in the Finnish population which has genetic features comparable to the Sardinian one, where the historical, cultural and geographical isolation may have selected specific genetic variants as susceptibility genes for breast cancer [33].
###end p 45
###begin p 46
###xml 65 73 65 73 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA1-2 </italic>
###xml 102 103 102 103 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1</xref>
###xml 109 132 109 132 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA2 c.8764_8765delAG </italic>
###xml 136 159 136 159 <italic xmlns:xlink="http://www.w3.org/1999/xlink">c.3950_3952delTAGinsAT </italic>
###xml 293 316 293 316 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA2 c.8764_8765delAG </italic>
###xml 428 430 428 430 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B11">11</xref>
###xml 431 433 431 433 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B14">14</xref>
###xml 489 495 489 495 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA2 </italic>
###xml 631 633 631 633 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B11">11</xref>
###xml 652 680 652 680 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA2 c.3950_3952delTAGinsAT</italic>
###xml 868 870 868 870 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B19">19</xref>
###xml 877 883 877 883 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA1 </italic>
###xml 1047 1053 1047 1053 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA1 </italic>
###xml 1207 1228 1207 1228 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA1 c.916_917delTT </italic>
###xml 1312 1314 1312 1314 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B34">34</xref>
###xml 1412 1420 1412 1420 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA1-2 </italic>
###xml 1662 1679 1662 1679 <italic xmlns:xlink="http://www.w3.org/1999/xlink">c.8764_8765delAG </italic>
###xml 1714 1715 1714 1715 <italic xmlns:xlink="http://www.w3.org/1999/xlink">b</italic>
###xml 1813 1819 1813 1819 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA2 </italic>
###xml 1856 1862 1856 1862 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA1 </italic>
###xml 1878 1879 1878 1879 <italic xmlns:xlink="http://www.w3.org/1999/xlink">c</italic>
###xml 1967 1973 1967 1973 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA1 </italic>
The geographical origin of the families positive for deleterious BRCA1-2 mutations is shown in Figure 1. The BRCA2 c.8764_8765delAG and c.3950_3952delTAGinsAT variants were previously described as founder mutations in North and Middle Sardinia, respectively. In particular, cases carrying the BRCA2 c.8764_8765delAG mutation belonged to unrelated families originating from different villages in the northern part of the island [11,14]; most of families genotyped with markers flanking the BRCA2 gene at 13q12-q13 locus were demonstrated to share a large haplotype, not found in control chromosomes from the same geographical area [11]. Conversely, the BRCA2 c.3950_3952delTAGinsAT, which was previously reported as a founder mutation, was instead running in families belonging to a single extended pedigree confined to a small village of the central part of Sardinia [19]. The BRCA1 variants occurred in families originating from different areas of the island without a defined geographical clustering, though about half of the cases carrying the BRCA1 mutations originated from the South Sardinia. Interestingly, in three unrelated families from the South and Middle Sardinia we identified carriers of the BRCA1 c.916_917delTT mutation that has been reported in breast-ovarian cancer families from South Italy [34]. Altogether, the geographical distribution of the genetic variants in the island, suggests that BRCA1-2 mutations are related to the specific three large areas of Sardinia, which reflects its ancient history: a) the North area, delimited by the mountain chain crossing Sardinia and linguistically different from the rest of the island (where the c.8764_8765delAG variant acts as founder mutation); b) the Middle area, land of the ancient Sardinian population and domain of pastoral culture (where BRCA2 mutations are still more common than BRCA1 mutations); and c) the South-West area, with many Phoenician and Carthaginian archeological sites (where BRCA1 mutations are prevalent).
###end p 46
###begin p 47
###xml 12 20 12 20 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA1-2 </italic>
Majority of BRCA1-2 germline mutations identified in Sardinian families is unique: most of the variants were detected in single families and 6 were novel mutations.
###end p 47
###begin p 48
###xml 19 25 19 25 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA1 </italic>
###xml 28 34 28 34 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA2 </italic>
###xml 187 193 187 193 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA2 </italic>
###xml 204 206 204 206 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B30">30</xref>
###xml 234 240 234 240 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA1 </italic>
###xml 244 250 244 250 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA2 </italic>
###xml 334 336 334 336 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B35">35</xref>
###xml 337 339 337 339 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B36">36</xref>
###xml 370 376 370 376 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA1 </italic>
###xml 426 428 426 428 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B37">37</xref>
###xml 429 431 429 431 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B38">38</xref>
###xml 448 454 448 454 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA2 </italic>
###xml 488 494 488 494 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA1 </italic>
###xml 598 621 598 621 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA2 c.8764_8765delAG </italic>
###xml 652 658 652 658 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA2 </italic>
###xml 730 732 730 732 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B39">39</xref>
###xml 777 783 777 783 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA2 </italic>
###xml 907 909 907 909 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B40">40</xref>
###xml 805 808 <span type="species:ncbi:9606">men</span>
The frequencies of BRCA1 or BRCA2 mutations among breast-ovarian cancer families varies widely between populations world-wide: Icelandic breast cancer families present almost exclusively BRCA2 mutations [30], roughly equal numbers of BRCA1 and BRCA2 mutations have been described in French Canadian or British breast cancer families [35,36], while a clear prevalence of BRCA1 mutations has been observed in the United States [37,38]. In this study BRCA2 mutations were more frequent than BRCA1 mutations, although it should be taken into account that a high proportion of families are carrying the BRCA2 c.8764_8765delAG founder mutation. Mutations in BRCA2 gene have been detected in up to 40% of male breast cancers in Iceland [39]; in our isolated population, we detected a BRCA2 mutation in 1/14 (7%) men with breast cancer with a frequency similar to that reported for male breast cancers in USA (4%) [40]. Again, these findings suggest that other environmental and/or genetic factors are contributing to the susceptibility to male breast cancer in Sardinia.
###end p 48
###begin p 49
###xml 103 109 103 109 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA1 </italic>
###xml 113 119 113 119 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA2 </italic>
###xml 138 140 138 140 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B41">41</xref>
###xml 243 251 243 251 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA1-2 </italic>
###xml 418 426 418 426 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA1-2 </italic>
###xml 691 697 691 697 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA1 </italic>
###xml 701 707 701 707 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA2 </italic>
###xml 378 386 <span type="species:ncbi:9606">patients</span>
Specific pathological features have been reported in hereditary breast cancer with differences between BRCA1 and BRCA2 associated tumors [41]. In our series, the analysis of clinico-pathological characteristics showed some differences between BRCA1-2 wild type and mutation carriers. Though no correlation with the stage of disease (the main prognostic factor for breast cancer patients) was observed, the presence of BRCA1-2 mutations were significantly associated with some pathological characteristics (higher tumor grading, lack of expression of estrogen/progesterone receptors) which are recognized to have a negative impact on prognosis. Unfortunately, data from mutation screening of BRCA1 and BRCA2 were combined for the statistical analysis due to the low number of positive cases for each single gene in our series, although distinct differences in both molecular pathology and histopathology have been shown according to the specific carrier status.
###end p 49
###begin title 50
Conclusion
###end title 50
###begin p 51
###xml 78 79 78 79 <italic xmlns:xlink="http://www.w3.org/1999/xlink">a</italic>
###xml 95 101 95 101 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA1 </italic>
###xml 105 111 105 111 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA2 </italic>
###xml 163 164 163 164 <italic xmlns:xlink="http://www.w3.org/1999/xlink">b</italic>
###xml 220 221 220 221 <italic xmlns:xlink="http://www.w3.org/1999/xlink">c</italic>
###xml 295 303 295 303 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA1-2 </italic>
###xml 558 566 558 566 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA1-2 </italic>
###xml 615 616 615 616 <italic xmlns:xlink="http://www.w3.org/1999/xlink">a</italic>
###xml 668 669 668 669 <italic xmlns:xlink="http://www.w3.org/1999/xlink">b</italic>
###xml 731 732 731 732 <italic xmlns:xlink="http://www.w3.org/1999/xlink">c</italic>
###xml 384 392 <span type="species:ncbi:9606">patients</span>
###xml 605 613 <span type="species:ncbi:9606">patients</span>
###xml 650 657 <span type="species:ncbi:9606">patient</span>
In summary, our results on the entire Sardinian population demonstrated that: a) prevalence of BRCA1 and BRCA2 mutations is 10% in familial breast-ovarian cancer; b) the spectrum of mutations among Sardinians is unique; c) some specific phenotypic features may be predictive for the presence of BRCA1-2 germline mutations and should be therefore considered when counselling Sardinian patients about undergoing genetic testing. On this regard, the fulfilment of one or more of the following criteria seems to increase the probability to detect a predisposing BRCA1-2 mutation among Sardinian breast cancer patients: a) high-risk classification of the patient's family; b) presence of at least one family member with ovarian cancer; c) occurrence of synchronous or asynchronous bilateral breast carcinoma.
###end p 51
###begin p 52
###xml 57 63 57 63 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA1 </italic>
###xml 67 73 67 73 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA2 </italic>
###xml 219 225 219 225 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA1 </italic>
###xml 228 234 228 234 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA2 </italic>
Our findings further confirm that mutation frequency for BRCA1 and BRCA2 as cancer susceptibility genes for breast-ovarian carcinoma needs to be evaluated in each distinct geographical area. Finally, the absence of any BRCA1 or BRCA2 mutation in majority of "high-risk" families with breast-ovarian cancer support the general hypothesis that additional breast cancer susceptibility genes remain to be identified.
###end p 52
###begin title 53
Competing interests
###end title 53
###begin p 54
The authors declare that they have no competing interests.
###end p 54
###begin title 55
Authors' contributions
###end title 55
###begin p 56
###xml 360 368 <span type="species:ncbi:9606">patients</span>
GP, AL, AU, carried out the molecular genetic studies, participated in the sequence alignment and drafted the manuscript. PF, GP, MP, ML, participated to the DHPLC analysis and resequencing. AG, AC, AC, FT participated in the collection and assembly of clinical data. MB performed the statistical analysis. AF, SO, CF, MCS, GL participated in the provision of patients and revision of the histological records. LC participated in the design and coordination of the study, GP participated in the design and coordination of the study and helped to draft the manuscript, MM contributed to the study conception, obtained financial support and revised the manuscript. All authors read and approved the final manuscript.
###end p 56
###begin title 57
Pre-publication history
###end title 57
###begin p 58
The pre-publication history for this paper can be accessed here:
###end p 58
###begin p 59

###end p 59
###begin title 60
Acknowledgements
###end title 60
###begin p 61
###xml 23 31 <span type="species:ncbi:9606">patients</span>
We are grateful to the patients and their families who partecipated to this study. Work was supported by Italian Ministry of Health "Progetto Ricerca Finalizzata", Sardinia Regional Government (Regione Autonoma Sardegna), Italian Association for Research on Cancer (AIRC) and Fondazione Banco di Sardegna.
###end p 61
###begin article-title 62
Global cancer statistics 2002
###end article-title 62
###begin article-title 63
Cancer incidence in Sassari Province (1998-2002)
###end article-title 63
###begin article-title 64
Genome-wide association study identifies novel breast cancer susceptibility loci
###end article-title 64
###begin article-title 65
Common variants on chromosomes 2q35 and 16q12 confer susceptibility to estrogen receptor-positive breast cancer
###end article-title 65
###begin article-title 66
###xml 73 78 73 78 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA1</italic>
A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1
###end article-title 66
###begin article-title 67
###xml 56 61 56 61 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA2</italic>
Identification of the breast cancer susceptibility gene BRCA2
###end article-title 67
###begin article-title 68
Breast cancer genes - what are the real risks?
###end article-title 68
###begin article-title 69
The Breast Cancer Information Core: Database Design, Structure, and Scope
###end article-title 69
###begin article-title 70
The Breast Cancer Information Core
###end article-title 70
###begin article-title 71
###xml 0 5 0 5 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA </italic>
BRCA mutations in Italian breast/ovarian cancer families
###end article-title 71
###begin article-title 72
###xml 28 34 28 34 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA2 </italic>
Identification of a founder BRCA2 mutation in Sardinia
###end article-title 72
###begin article-title 73
###xml 34 40 34 40 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA1 </italic>
Reconstructing the Genealogy of a BRCA1 Founder Mutation by Phylogenetic Analysis
###end article-title 73
###begin article-title 74
###xml 46 51 46 51 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA1</italic>
Founder mutations account for the majority of BRCA1-attributable hereditary breast/ovarian cancer cases in a population from Tuscany, Central Italy
###end article-title 74
###begin article-title 75
###xml 0 6 0 6 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA1 </italic>
###xml 10 16 10 16 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA2 </italic>
BRCA1 and BRCA2 germline mutations in Sardinian breast cancer families and their implications for genetic counseling
###end article-title 75
###begin article-title 76
Molecular characterization of beta-thalassemia in the Sardinian population
###end article-title 76
###begin article-title 77
###xml 21 29 <span type="species:ncbi:9606">patients</span>
Mutation analysis in patients of Mediterranean descent with Wilson disease: identification of 19 novel mutations
###end article-title 77
###begin article-title 78
The inter-regional distribution of HLA class II haplotypes indicates the suitability of the Sardinian population for case-control association studies in complex diseases
###end article-title 78
###begin article-title 79
###xml 89 97 <span type="species:ncbi:9606">patients</span>
Spectrum and prevalence of BRCA1 and BRCA2 germline mutations in Sardinian breast cancer patients through a hospital-based screening
###end article-title 79
###begin article-title 80
Identification of a founder BRCA2 mutation in Sardinian breast cancer families
###end article-title 80
###begin article-title 81
###xml 55 60 <span type="species:ncbi:9606">human</span>
A simple salting out procedure for extracting DNA from human nucleated cells
###end article-title 81
###begin article-title 82
National Center for Biotechnology Information Blast
###end article-title 82
###begin article-title 83
###xml 36 41 <span type="species:ncbi:9606">human</span>
Nomenclature for the description of human sequence variations
###end article-title 83
###begin article-title 84
###xml 0 5 <span type="species:ncbi:9606">Human</span>
Human Gene Mutation Database
###end article-title 84
###begin article-title 85
###xml 9 14 <span type="species:ncbi:9606">Human</span>
National Human Genome Research Institute
###end article-title 85
###begin article-title 86
The value of histological grade in breast cancer: experience from a large study with long-term follow-up
###end article-title 86
###begin article-title 87
TNM classification of malignant tumours, 5th edition(1997). Union Internationale Contre le Cancer and the American Joint Committee on Cancer
###end article-title 87
###begin article-title 88
Genetic variation in prehistoric Sardinia
###end article-title 88
###begin article-title 89
Magnitude and distribution of linkage disequilibrium in population isolates and implications for genome-wide association studies
###end article-title 89
###begin article-title 90
Genetic alterations in hereditary breast cancer
###end article-title 90
###begin article-title 91
###xml 9 15 9 15 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA2 </italic>
A single BRCA2 mutation in male and female breast cancer families from Iceland with varied cancer phenotypes
###end article-title 91
###begin article-title 92
###xml 25 31 25 31 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA1 </italic>
Founder mutations in the BRCA1 gene in Polish families with breast-ovarian cancer
###end article-title 92
###begin article-title 93
###xml 56 68 56 68 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA1/BRCA2 </italic>
Large regional differences in the frequency of distinct BRCA1/BRCA2 mutations in 517 Dutch breast and/or ovarian cancer families
###end article-title 93
###begin article-title 94
###xml 18 24 18 24 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA1 </italic>
###xml 28 34 28 34 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA2 </italic>
Low proportion of BRCA1 and BRCA2 mutations in Finnish breast cancer families: evidence for additional susceptibility genes
###end article-title 94
###begin article-title 95
###xml 0 6 0 6 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA1 </italic>
BRCA1 genetic testing in 106 breast and ovarian cancer families from southern Italy (Sicily): a mutation analyses
###end article-title 95
###begin article-title 96
###xml 8 14 8 14 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA1 </italic>
###xml 18 24 18 24 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA2 </italic>
Founder BRCA1 and BRCA2 mutations in French Canadian breast and ovarian cancer families
###end article-title 96
###begin article-title 97
###xml 14 20 14 20 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA1 </italic>
###xml 24 30 24 30 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA2 </italic>
###xml 48 56 <span type="species:ncbi:9606">patients</span>
Prevalence of BRCA1 and BRCA2 gene mutations in patients with early-onset breast cancer
###end article-title 97
###begin article-title 98
###xml 53 59 53 59 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA1 </italic>
###xml 63 69 63 69 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA2 </italic>
Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The Breast Cancer Linkage Consortium
###end article-title 98
###begin article-title 99
###xml 13 25 13 25 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA1/BRCA2 </italic>
Frequency of BRCA1/BRCA2 mutations in a population-based sample of young breast carcinoma cases
###end article-title 99
###begin article-title 100
###xml 31 37 31 37 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA2 </italic>
The Icelandic founder mutation BRCA2 999del5: analysis of expression
###end article-title 100
###begin article-title 101
###xml 56 62 56 62 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA1 </italic>
###xml 65 70 65 70 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA2</italic>
Cancer Risks for Male Carriers of Germline Mutations in BRCA1 or BRCA2: A Review of the Literature
###end article-title 101
###begin article-title 102
Clinical Outcomes of Breast Cancer in Carriers of BRCA1 and BRCA2 Mutations
###end article-title 102

